FEATURE ARTICLES

What’s The Backbone Of Vivek Ramaswamy’s Success?
What’s The Backbone Of Vivek Ramaswamy’s Success?

Read why Roivant Sciences founder and CEO Vivek Ramaswamy has been portrayed by some as being the next wizard of Wall Street for “conjuring drug companies from thin air.”

More featured articles

ALSO IN THIS MONTH'S ISSUE

  • Provider Consolidation Raising Costs And Undermining Competition
    Provider Consolidation Raising Costs And Undermining Competition

    As Republicans attempt to recover from their face-plant on repealing and replacing Obamacare, policymakers are grappling with how to address the growing problem of healthcare provider consolidation, which appears to be raising costs and undermining competition.

  • Are We Encouraging The New Pharma Entrepreneurs?
    Are We Encouraging The New Pharma Entrepreneurs?

    Many of the company founders I’ve spoken with often admit that had they known how difficult starting a biopharmaceutical company would be, they would have likely never embarked on the journey in the first place.

  • Tackling The Challenges Of A Rare-Disease Clinical Trial
    Tackling The Challenges Of A Rare-Disease Clinical Trial

    Regulatory agencies today are looking for Phase 3 trials to demonstrate a reduction in mortality as well as greater patient mobility. Unfortunately, Phase 3 trials also cost a lot of money to run, making them a challenge for small biotech firms.

  • Janssen Turns Clinical Data Over To Patients
    Janssen Turns Clinical Data Over To Patients

    Andreas Koester, MD, Ph.D., global head, R&D operations innovation at Janssen, discusses how the company is attempting to make patient data available to participants while a clinical trial is underway.

  • The Worldwide War On Counterfeit Medicines
    The Worldwide War On Counterfeit Medicines

    It’s a sobering trend for the pharmaceutical industry. The counterfeit medicines market is growing at twice the rate of the market for legitimate prescription drugs. So what can be done?

More from Life Science Leader

SPECIAL EDITION: 2017 CMO LEADERSHIP AWARDS

 

Read all the exclusive content — including who our CMO award winners are this year — in the 2017 CMO Awards Special Edition.

 

 

WEB-EXCLUSIVE EDITORIAL

  • Biosimilars: An Evolving Commercial Model
    Biosimilars: An Evolving Commercial Model

    In this series of articles, the biosimilar market has been carefully examined to help identify the ways in which it is on the brink of considerable and rapid change.

  • Impact Of International Trade Regulations
    Impact Of International Trade Regulations

    The significant number of national and international trade regulations are challenging for the development of logistics strategies for global clinical research. Identifying the similarities, differences and obstacles pharmaceutical companies face while importing and exporting medicinal products for clinical trials creates an opportunity to streamline the process, remove barriers, and improve efficiency.

  • Biosimilars: Differentiating And Surviving The Cost Of Entry
    Biosimilars: Differentiating And Surviving The Cost Of Entry

    This is the third article in a series on biosimilars. The first two pieces layout the background of the biosimilar market to date and the challenges shaping the market. This article sets out to explain how biosimilar companies are achieving differentiation and what it will take to establish market share.

  • China’s Healthcare Reforms: Double-Edged Sword For The Pharmaceutical Industry
    China’s Healthcare Reforms: Double-Edged Sword For The Pharmaceutical Industry

    Without change, China’s current healthcare system will become unaffordable. The latest round of reforms are aimed at ensuring sustainability by reducing costs. The reforms, if implemented effectively, will have a significant impact on companies operating in the sub-sectors of medical devices, pharmaceuticals, and healthcare services.

  • The Players In The Biosimilar Market
    The Players In The Biosimilar Market

    This article provides details of the different players that exist in the complex biosimilar market, all of which have different characteristics, histories, reasons for entry, internal capabilities and resources available to support their programs.

More web-exclusive editorial

BEYOND THE PRINTED PAGE

  • CSL Limited CEO Shares Insights Beyond Just How To Grow Revenue

    Being the head of any Big Pharma is bound to test an executive’s work-life balance. But when that Big Pharma is headquartered in Australia, and the company prides itself on being a “global operation,” maintaining any kind of work-life balance is a formidable task. “I’m not the poster child for how to strive for work-life balance,” admits Paul Perreault, CEO and managing director of CSL.

  • 9 Questions With Takeda Oncology’s Chief Counsel And Head Of Patient Advocacy

    In 2002 Liz Lewis joined Takeda where she is currently chief counsel and head of patient advocacy at Takeda Oncology. Lewis sat down with me to share how she helped enhance Takeda Oncology’s patient advocacy organization.

  • What Will The Global Biopharmaceutical Industry Look Like In 2027: Trendsetter Series Part 4 of 4

    The executive-level participation for Life Science Leader magazine's signature 2017 Outlook issue had an overwhelming. This year’s feature article involved 13 executive life science leaders! In part four of this series, which is a supplement to the feature magazine article, we pose the question, “Looking even further ahead, what is your vision for how the global biopharmaceutical industry might look in the year 2027?”

More Beyond The Printed Page Articles

LIFE SCIENCE TRAINING INSTITUTE COURSES

Bioprocess Facility Design - Layout Rules and Configurations May 10, 2017
1pm-2:30pm EDT, Online Training
Cloud Computing In A GxP Environment: Three Key Success Factors May 16, 2017
1pm-2:30pm EDT, Online Training
Monitoring Medical Device / ISO 14155 GCP June 8, 2017
1pm-2:30pm EDT, Online Training
More training courses

APRIL 2017 DIGITAL EDITION

2017 CMO AWARDS SPECIAL EDITION

BLOGS

  • From Disney’s World To DC — City Hopping For ENDO & AACR
    From Disney’s World To DC — City Hopping For ENDO & AACR

    Orlando, the city of warmth and happiness by design, hosted the Endocrine Society’s annual ENDO event this year, overlapping the Washington, DC-hosted AACR, the yearly confab by the American Association for Cancer Research, by several days. I was determined to visit both shows.

  • Who Is The Biopharmaceutical Industry CEO Of The Year?
    Who Is The Biopharmaceutical Industry CEO Of The Year?

    I’ve been thinking, if you were going to name someone to be the biopharmaceutical industry CEO of the year, who would it be? But even more important than the who is the why. What criteria would you use? I’ve been looking through a bunch of articles that list top influencers for our industry, and the criterion for inclusion seems pretty subjective. There are media outlets that employ a variety of objective measures (i.e., company performance). And while perhaps better than a completely subjective approach, we all know that having great sales performance doesn’t necessarily make you a great leader. One of the best methodologies I have seen for naming a top CEO was done by the Harvard Business Review in 2015. It included financial data (weighted at 80 percent) and a measurement of a company’s environmental, social, and governance (ESG) performance (weighted at 20 percent).

More blogs

@LIFESCILEADER1

2016 CRO AWARDS SPECIAL EDITION

 UPCOMING EVENTS

Cleanroom Microbiology – A Foundational Introduction April 27, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Computer Systems Validation (CSV) – Avoiding The Top Five Regulatory Pitfalls May 2, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Data Integrity in a GxP Environment – Top Tips for Compliance May 3, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Understanding and Implementing the New EU Regulation for Initiating and Conducting Clinical Trials May 4, 2017
1pm-2:30pm EDT, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Reacting to “Human Error” – Moving Beyond “Retraining” As A Response May 9, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
More events